Protox Therapeutics Adds Rohm, Sobti to Board

Publicly traded Protox Therapeutics Inc. has added William Rohn and Amit Sobti to its board of directors. Rohn is a former chief operating officer for biotech company Biogen-Idec. Sobti is a principal with Warburg Pincus, where he focuses on investments in healthcare. He worked previously at Rhone Capital, a mid-market private equity firm.

PRESS RELEASE
Protox Therapeutics Inc. is appointing William Rohn and Amit Sobti to the company’s board of directors.

“We are delighted to welcome Bill and Amit to help guide Protox through the exciting phase of the company’s progress,” said Dr. Fahar Merchant, President & CEO of Protox. “Their insights and experience with product commercialization and the capital markets from both the large pharmaceutical arena and the biotech industry will be invaluable. Their appointment is just another indication of our commitment to build and strengthen our board and to enhance our ability to move the company to the next level.”

Bill Rohn has over 30 years of experience as a senior executive in the pharmaceutical and biotech industry. He retired in January of 2005 from the position of Chief Operating Officer at Biogen-Idec, a major global biotech company. He played an instrumental role in the $6.8 billion merger of IDEC Pharmaceuticals and Biogen Inc. Prior to serving as COO of the combined company, Bill was the President and Chief Operating Officer of IDEC Pharmaceuticals where he helped transform IDEC from a small research organization into a very successful, biotechnology company. Before moving to the fledgling biotech industry, Bill spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibilities at Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer). In addition to his role at Protox, Bill serves on the Board of Directors of Cerus Corporation, Intellikine, Cebix Inc., and the La Jolla Institute of Allergy and Immunology.

Amit Sobti is a principal with Warburg Pincus where he focuses on investments in healthcare. Prior to joining Warburg Pincus, he worked at Rhone Capital, a mid-market private equity firm, and at Merrill Lynch in the Mergers & Acquisitions group. Amit received an A.B. in Business Economics and an A.B. in Computer Science from Brown University. In addition to Protox, Amit also serves on the Board of Directors of ReSearch Pharmaceutical Services, Inc.